GlaxoSmithKline S.A.E (EGX: BIOC)
Egypt
· Delayed Price · Currency is EGP 42.20
-3.60 (-7.86%)
At close: Oct 15, 2024
GlaxoSmithKline S.A.E Cash Flow Statement
Financials in millions EGP. Fiscal year is January - December.
Millions EGP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 133.44 | 60.46 | 735.38 | 154.64 | 28.13 | 142.61 | Upgrade
|
| Depreciation & Amortization | 49.92 | 47.79 | 49.81 | 57.19 | 28.4 | 20.31 | Upgrade
|
| Loss (Gain) From Sale of Assets | 4.74 | -0.17 | -5.94 | -0.24 | -0.15 | -2.35 | Upgrade
|
| Asset Writedown & Restructuring Costs | 137.65 | 137.65 | 101 | - | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | 34.41 | 18.12 | -12.15 | 9.21 | 19.49 | -26.97 | Upgrade
|
| Provision & Write-off of Bad Debts | 69.08 | -18.66 | 11.01 | 30.79 | 56.87 | 2.62 | Upgrade
|
| Other Operating Activities | 264.35 | 24.11 | -530.26 | 89.78 | 222.88 | 226.97 | Upgrade
|
| Change in Accounts Receivable | -262.55 | -366.5 | -231.15 | -18.53 | -147.25 | 25.19 | Upgrade
|
| Change in Inventory | -424.61 | -224.74 | -47.2 | -42.95 | -84.47 | -94.41 | Upgrade
|
| Change in Accounts Payable | 243.41 | 156.24 | -322.32 | 45.45 | -28.54 | -27.75 | Upgrade
|
| Change in Other Net Operating Assets | -90.25 | 467.99 | -82.97 | -133.15 | -96.51 | -328.78 | Upgrade
|
| Operating Cash Flow | 159.58 | 302.27 | 1,036 | 192.19 | -1.17 | -62.56 | Upgrade
|
| Operating Cash Flow Growth | 38.79% | -70.82% | 439.06% | - | - | - | Upgrade
|
| Capital Expenditures | -90.28 | -77.08 | -48.76 | -35.76 | -53.67 | -133.12 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.08 | 5.42 | 6.99 | 0.61 | 0.17 | 2.64 | Upgrade
|
| Other Investing Activities | 133.03 | 157.15 | -200 | - | - | - | Upgrade
|
| Investing Cash Flow | 42.83 | 85.5 | -241.77 | -35.15 | -53.5 | -130.48 | Upgrade
|
| Short-Term Debt Issued | - | - | - | - | - | 235.16 | Upgrade
|
| Total Debt Issued | 2.91 | - | - | - | - | 235.16 | Upgrade
|
| Short-Term Debt Repaid | - | - | -118.21 | -27.52 | -89.43 | - | Upgrade
|
| Long-Term Debt Repaid | - | -28.98 | -19.21 | -24.11 | - | - | Upgrade
|
| Total Debt Repaid | -55.18 | -28.98 | -137.43 | -51.63 | -89.43 | - | Upgrade
|
| Net Debt Issued (Repaid) | -52.27 | -28.98 | -137.43 | -51.63 | -89.43 | 235.16 | Upgrade
|
| Common Dividends Paid | -42.51 | -131.59 | -111.04 | -5.58 | -5.58 | -5.58 | Upgrade
|
| Other Financing Activities | -27.75 | 16.3 | -33.5 | -48.42 | -79.37 | -91.86 | Upgrade
|
| Financing Cash Flow | -122.54 | -144.28 | -281.97 | -105.63 | -174.38 | 137.73 | Upgrade
|
| Net Cash Flow | 79.87 | 243.49 | 512.29 | 51.41 | -229.05 | -55.31 | Upgrade
|
| Free Cash Flow | 69.3 | 225.2 | 987.26 | 156.43 | -54.84 | -195.68 | Upgrade
|
| Free Cash Flow Growth | 62.03% | -77.19% | 531.14% | - | - | - | Upgrade
|
| Free Cash Flow Margin | 2.67% | 10.05% | 54.15% | 8.63% | -2.75% | -11.48% | Upgrade
|
| Free Cash Flow Per Share | 0.83 | 2.70 | 11.82 | 1.87 | -0.66 | -2.34 | Upgrade
|
| Cash Interest Paid | 37.96 | 37.96 | 33.5 | 48.67 | 79.91 | - | Upgrade
|
| Cash Income Tax Paid | 48.36 | 173.04 | 10.72 | 29.97 | 8.74 | 54.52 | Upgrade
|
| Levered Free Cash Flow | 224.19 | 174.2 | 108.37 | 49.65 | 95.72 | -294.82 | Upgrade
|
| Unlevered Free Cash Flow | 241.54 | 197.93 | 129.31 | 80.07 | 145.66 | -236.92 | Upgrade
|
| Change in Net Working Capital | 97.09 | 48.73 | -118.68 | 92.7 | -44.36 | 291.34 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.